Black Rock Inc. Enochian Biosciences Inc Transaction History

Black Rock Inc.

$4.23 Trillion
Q1 2024

A detailed history of Black Rock Inc. transactions in Enochian Biosciences Inc stock. As of the latest transaction made, Black Rock Inc. holds 314,314 shares of ENOB stock, worth $1.45 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

314,314

Previous 304,656 3.17%

Holding current value

$1.45 Million

Previous $1.4 Million 3.14%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	N/A	9,658 Added 3.17%	314,314 $1.45 Million
Q4 2023 Feb 13, 2024	BUY	$4.3 - $4.7 $91,104 - $99,578	21,187 Added 7.47%	304,656 $1.4 Million
Q3 2023 Nov 13, 2023	BUY	$0.0 - $4.46 $0 - $136,975	30,712 Added 12.15%	283,469 $1.26 Million
Q2 2023 Aug 11, 2023	SELL	$0.4 - $1.3 $391,690 - $1.27 Million	-979,227 Reduced 79.48%	252,757 $144,000
Q1 2023 May 12, 2023	BUY	$0.91 - $1.31 $140,816 - $202,713	154,743 Added 14.36%	1,231,984 $1.13 Million

Q4 2022 Feb 13, 2023	BUY	$1.03 - $2.13 $35,874 - $74,187	34,830 Added 3.34%	1,077,241 $1.11 Million
Q3 2022 Nov 14, 2022	SELL	$1.7 - $2.86 $23,910 - $40,225	-14,065 Reduced 1.33%	1,042,411 $1.89 Million
Q2 2022 Aug 12, 2022	BUY	$1.93 - $8.73 $1.65 Million - $7.48 Million	856,390 Added 428.01%	1,056,476 $2.04 Million
Q1 2022 May 12, 2022	BUY	$4.42 - $9.0 $40,040 - $81,531	9,059 Added 4.74%	200,086 $1.65 Million
Q4 2021 Feb 10, 2022	BUY	$6.71 - $12.55 $643,374 - $1.2 Million	95,883 Added 100.78%	191,027 $1.39 Million
Q3 2021 Nov 09, 2021	SELL	$4.56 - $7.88 $215,587 - $372,550	-47,278 Reduced 33.2%	95,144 $640,000
Q2 2021 Aug 11, 2021	BUY	$2.94 - $6.79 $418,720 - $967,045	142,422 New	142,422 $707,000

Others Institutions Holding ENOB

# of Institutions

Shares Held

7.25M

Call Options Held

16K

Put Options Held

12.5K

View Full List

About Enochian Biosciences Inc

Ticker ENOB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,950,000
Market Cap $244M
Description
Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company's lead candidate includes ENOB-HV-01 for au...

More about ENOB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account